TNDM Intrinsic Value Calculation – Lisanti Capital Growth LLC reduces stake in Tandem Diabetes Care by over a quarter in third quarter
November 12, 2024
☀️Trending News
Tandem Diabetes Care ($NASDAQ:TNDM) is a leading medical technology company that specializes in developing and manufacturing innovative products for people living with diabetes. Their flagship product is the t:slim X2, a touchscreen insulin pump that combines advanced technology with user-friendly design. The company’s stock has been steadily growing in recent years, gaining attention from both investors and patients alike.
However, in the third quarter of this year, Lisanti Capital Growth LLC, a California-based investment firm, decreased its stake in Tandem Diabetes Care by over a quarter. This decision marks a significant change in their position within the company. With this recent reduction in their stake, it is important to understand the reasons behind their decision. One possible reason for this reduction could be due to Tandem Diabetes Care’s recent financial performance. This could have caused concern for investors like Lisanti Capital Growth LLC, leading them to decrease their stake in the company. Another factor could be the potential competition in the insulin pump market. Tandem Diabetes Care faces tough competition from other medical technology companies, such as Medtronic and Insulet. These companies are constantly developing new and advanced products, which could pose a threat to Tandem Diabetes Care’s market share. Despite this reduction in stake, Tandem Diabetes Care remains a promising company with strong potential for growth. The company has recently received FDA approval for their t:slim X2 insulin pump with Control-IQ technology, which is expected to be a game-changer in the diabetes market.
Additionally, they have ongoing partnerships and collaborations that could lead to further innovation and growth. In conclusion, while it may be concerning to see a major investor reduce their stake in Tandem Diabetes Care, it is important to note that this decision does not necessarily reflect the company’s overall performance. Tandem Diabetes Care continues to be a leader in the diabetes technology market and has potential for future growth and success.
Price History
As a company that specializes in developing and selling medical devices for people with diabetes, Tandem Diabetes Care has been a popular choice for investors looking to capitalize on the growing demand for diabetes management solutions. The fact that the stock price dropped significantly after news of the reduced stake was announced only adds fuel to the fire. It is worth noting that this reduction in stake does not necessarily mean that Tandem Diabetes Care is facing financial difficulties or that its products are no longer in demand. Additionally, Tandem Diabetes Care has recently received FDA approval for its t:slim X2 insulin pump with Control-IQ technology, which has been well received by customers and healthcare professionals. While Lisanti Capital Growth LLC’s decision to decrease its stake may raise some concerns, it is also important to keep in mind that this is just one investor’s move and does not necessarily reflect the overall sentiment towards Tandem Diabetes Care. It will be interesting to see how the company performs in the coming months and if other investors follow suit in reducing their stakes as well.
However, it is important to look at the bigger picture and consider all factors before jumping to conclusions about the company’s future. Tandem Diabetes Care’s recent financial performance and product developments suggest that it still has potential for growth and success in the diabetes management industry. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for TNDM. More…
| Total Revenues | Net Income | Net Margin |
| 747.72 | -222.61 | -21.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for TNDM. More…
| Operations | Investing | Financing |
| -31.81 | -85.74 | 4.11 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for TNDM. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 952.66 | 639.03 | 4.78 |
Key Ratios Snapshot
Some of the financial key ratios for TNDM are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 14.4% | – | -28.4% |
| FCF Margin | ROE | ROA |
| -11.2% | -42.4% | -14.0% |
Analysis – TNDM Intrinsic Value Calculation
As an analyst at GoodWhale, I have conducted a thorough examination of the wellness of TANDEM DIABETES CARE. Through our extensive analysis, we have found that the company is in good standing and has the potential for strong growth in the future. One key indicator of the company’s wellness is its intrinsic value. Our proprietary Valuation Line has calculated TANDEM DIABETES CARE’s intrinsic value to be around $66.6. This takes into account various factors such as financial performance, industry trends, and market conditions. This suggests that the company’s stock is currently undervalued. In fact, our analysis shows that TANDEM DIABETES CARE’s stock is currently trading at $30.6, which indicates a significant undervaluation of 54.1%. This presents an opportunity for investors to purchase the stock at a discounted price and potentially benefit from future growth. Based on our findings, we believe that TANDEM DIABETES CARE is a solid investment opportunity for those looking for long-term growth potential. The company’s strong financials and undervalued stock make it an attractive option in the market. As always, we recommend further research and due diligence before making any investment decisions. More…
Peers
The market for diabetes care products is highly competitive, with major players such as Tandem Diabetes Care Inc, NuVasive Inc, Avanos Medical Inc, and Penumbra Inc vying for market share. While each company has its own strengths and weaknesses, the competition between them is fierce, and it is often the case that one company’s success comes at the expense of its rivals.
– NuVasive Inc ($NASDAQ:NUVA)
NuVasive Inc is a medical device company that develops minimally-invasive surgical products and procedures for spine surgery. The company has a market cap of 2.17B as of 2022 and a Return on Equity of -1.33%. NuVasive’s products and procedures are designed to improve patient outcomes and minimize surgical invasiveness. The company’s products are used in a variety of spine surgeries, including lumbar, thoracic, and cervical procedures.
– Avanos Medical Inc ($NYSE:AVNS)
Avanos Medical Inc is a medical technology company that focuses on developing and commercializing minimally invasive medical devices. The company has a market cap of 957.63M as of 2022 and a Return on Equity of 2.85%. Avanos’ products are used in a variety of procedures, including pain management, gastrointestinal, urological, ENT, and vascular.
– Penumbra Inc ($NYSE:PEN)
As of 2022, Penumbra Inc has a market cap of 6.49B and a Return on Equity of -2.31%. The company is a medical device company that develops, manufactures and markets products for the treatment of neurovascular diseases.
Summary
Lisanti Capital Growth LLC, a major investor in Tandem Diabetes Care, Inc., reduced its stake in the company by nearly a third during the third quarter. This move caused the stock price to drop on the same day. This could indicate that the investor has concerns about the company’s prospects and decided to lower their exposure to it. It will be important to closely monitor any future actions taken by Lisanti Capital Growth LLC and other investors as it can provide insight into the overall sentiment towards Tandem Diabetes Care and its stock performance.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
